Problems with current pharmacologic treatment of Parkinson's disease

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 10-16

  Hurtig, Howard I ^a  

^a GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE; BENZATROPINE MESILATE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PROCYCLIDINE; SELEGILINE; TRIHEXYPHENIDYL;

AMNESIA; ARTICLE; BODY POSTURE; CONSTIPATION; DYSKINESIA; EDEMA; HUMAN; HYPOTENSION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0031106243     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6380     Document Type: Article

References (61)

1. 1. AHLSKOG, J. E. 1996. Treatment of early Parkinson's disease: Are complicated strategies justified? Mayo. Clin. Proc. 71: 659-670.
2. 2. BARBEAU, A. 1976. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch. Neurol. 33: 333-338.
3. 3. BARONTI, F., M. M. MOURADIAN, T. L. DAVID, et al. 1992. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann. Neurol. 32: 776-781.
4. 4. BERNHEIMER, H., W. BIRKMAYER, O. HORNYKIEWICZ. et al. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20: 415-455.
5. 5. BIRKMAYER, W., J. KNOLL, P. RIEDERER, et al. 1985. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J. Neural. Transm. 64: 113-127.
6. 6. BOYCE, S., N. M. J. RUPNAIK, M. J. STEVENTON, AND S. D. IVERSON. 1990. Nigrostriatal damage is required for induction of dyskinesias by L-Dopa in squirrel monkeys. Clin. Neuropharmacol. 5: 448-458.
7. 7. BRAVI, D., M. D. MOURADIAN, J. W. ROBERTS, et al. 1994. Wearing-off fluctuations in Parkinson's disease: Contributions of postsynaptic mechanisms. Ann. Neurol. 36: 27-31.
8. 8. BROWN, R. G., AND C. D. MARSDEN. 1984. How common is dementia in Parkinson's disease. Lancet 2: 1262-1265.
9. 9. BROWN, R. G., AND C. D. MARSDEN. 1988. Subcortical dementia: The neuropsychological evidence. Neuroscience 25: 363-387.
10. 10. CALNE, D. B. 1978. Dopaminergic agonists in the treatment of parkinsonism. Clin. Neuropharmacol. 3: 153-166.
11. 11. COTZIAS, G. C., M. H. VAN WOERT, AND L. M. SCHIFFER. 1967. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276: 374-379.
12. 12. COTZIAS, G., P. S. PAPAVASILIOU, AND R. CELLENE. 1969. Modification of parkinsonism: Chronic treatment with L-dopa. N. Engl. J. Med. 276: 337-345.
13. 13. DE LONG, M. 1996. Ten most commonly asked questions about pallidotomy. Neurologist 2: 191-195.
14. 14. DJALDETTI, R., AND E. MELAMED. 1996. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann. Neurol. 39: 400-404.
15. 15. ECKSTEIN, B., K. SHAW, AND G. M. STERN. 1973. Sustained release levodopa in parkinsonism. Lancet 1: 431-432.
16. 16. EDWARDS, L. L., E. M. M. QUIGLEY, AND R. F. PFEIFFER. 1992. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42: 726-732.
17. 17. FRIEDMAN, J. H., AND M. C. LANNON. Clozapine in idiopathic Parkinson's disease. Neurology 40: 1151-1152.
18. 18. GANCHER, S. T., J. G. NUTT, AND W. R. WOODWARD. 1992. Time course of tolerance to apomorphine in parkinsonism. Clin. Pharmacol. Ther. 52: 504-510.
19. 19. GOETZ, C. G., C. M. TANNER, R. H. GLANTZ, AND H. L. KLAWANS. 1985. Chronic agonist therapy for Parkinson's disease: A five year study of bromocriptine and pergolide. Neurology 35: 749-751.
20. 20. GOLBE, L. I., A. N. LIEBERMAN, M. D. MUENTER, et al. 1988. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. Neuropharmacol. 11: 45-55.
21. 21. GOWERS, W. R. 1988. Paralysis agitans. Pages 995-1014 in A Manual of Diseases of the Nervous System. Blakiston, Philadelphia.
22. 22. GRANDAS, F., S. T. GANCHER, M. RODRIQUEZ, et al. 1992. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin. Neuropharmacol. 15: 13-18.
23. 23. HOEHN, M., AND M. YAHR. 1967. Parkinsonism: Onset, progression and mortality. Neurology 17: 427-442.
24. 24. HORNYKIEWICZ, O. 1966. Dopamine and brain function. Pharmacol. Rev. 99: 925-962.
25. 25. HUGHES, A. J., S. E. DANIEL, S. BLANKSON, AND A. J. LEES. 1993. A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50: 140-148.
26. 26. HULETTE, C., S. MIRRA, W. WILKINSON, et al. 1995. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Neurology 45: 1991-1995.
27. 27. HURTIG, H. I. 1988. Advanced Parkinson's disease and complications of treatment. Pages 119-158 in M. B. Stern and H. I. Hurtig, Eds., The Comprehensive Management of Parkinson's Disease. PMA, New York.
28. 28. HURTIG, H. I., M. B. STERN, AND A. COLCHER. 1996. Living with Parkinson's disease. N. Engl. J. Med. 335: 130.
29. 29. HUTTON, J. T., J. L. MORRIS, D. F. BUSH, et al. 1989. Multi center controlled study of Sinemet CR vs. Sinemet 25/100 in advanced Parkinson's disease. Neurology 39(Suppl. 2): 67-72.
30. 30. JUNCOS, J. L., M. M. MOURADIAN, G. FABBRINI, et al. 1987. Levodopa methylester treatment of Parkinson's disease. Neurology 37: 1242-1245.
31. 31. KISH, S. J., K. SHANNAK, AND O. HORNYKIEWICZ. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318: 876-880.
32. 32. KOLLER, W. 1994. An algorithm for the management of Parkinson's disease. Neurology 44(Suppl. 1): S1-S52.
33. 33. KURLAN, R., K. P. ROTHFIELD, W. R. WOODWARD, et al. 1988. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 38: 419-421.
34. 34. LEE, T., P. SEEMAN, A. RAJPUT, et al. 1978. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1273: 59-61.
35. 35. MANYAN, B. V., AND S. SHONKWILER. 1994. Standard carbidopa-levodopa vs. controlled release carbidopa-levodopa in Parkinson's disease: a post-market analysis. Clin. Neuropharmacol. 17: 128-137.
36. 36. MARCONI, R., D. LEFEBVRE-CAPARROS, A. BONNET, et al. 1994. Levodopa-induced dyskinesia in Parkinson's disease: phenomenology and pathophysiology. Mov. Disord. 9: 2-12.
37. 37. MARSDEN, C. D., AND J. D. PARKES. 1977. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1: 345-349.
38. 38. MAYEUX, R., J. DENARO, N. HENENEGELDO, et al. 1992. A population-based investigation of Parkinson's disease with and without dementia. Arch. Neurol. 49: 492-497.
39. 39. MAYEUX, R., Y. STERN, K. MULVEY, AND L. COTE. 1985. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease. N. Engl. J. Med. 313: 724-728.
40. 40. MELAMED, E., F. HEFTI, D. J. PETTIBONE, et al. 1978. Aromatic L-amino acid decarboxylase in rat corpus striatum: Implications for action of L-Dopa in parkinsonism. Neurology 31: 651-655.
41. 41. MELAMED, E., V. BITTON, AND O. ZELIG. 1986. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. Clin. Neuropharmacol. 9: 182-188.
42. 42. MOURADIAN, M. M., I. J. E. HEUSER, F. BARONTI, et al. 1989. Pathogenesis of dyskinesia in Parkinson's disease. Ann. Neurol. 25: 523-526.
43. 43. MUENTER, M. D., AND G. M. TYCE. 1971. L-Dopa therapy of Parkinson's disease: Plasma L-Dopa concentration, therapeutic response and side effects. Mayo Clin. Proc. 46: 231-239.
44. 44. MUENTER, M. D., N. S. SHARPLESS, G. M. TYCE, AND F. L. DARLEY. 1977. Patterns of dystonia ("IDI" and "DID") in response to L-dopa therapy for Parkinson's disease. Mayo Clin. Proc. 52: 163-174.
45. 45. NARABAYASHI, H., T. KONDO, AND T. NAGATSU. 1984. L-Threo 3,4 dihydroxyphenylserine (L-Threo dops) for freezing symptom in parkinsonism. Add. Neurol. 40: 497-503.
46. 46. NUTT, J. G., J. H. CARTER, AND W. R. WOODWARD. 1994. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology 44: 1617-1622.
47. 47. NUTT, J. G., AND N. H. G. HOLFORD. 1996. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol. 39: 561-573.
48. 48. OGASAHARA, S., Y. NISHIKAWA, M. TAKAHASHI, et al. 1984. Dopamine metabolism in the central nervous system after discontinuation of L-Dopa therapy in patients with Parkinson's disease. J. Neurol. Sci. 66: 151-163.
49. 49. OLANOW, C. W., M. ALBERTS, J. STAKJCH, AND G. BURCH. 1987. A randomized blinded study of low dose bromocriptine versus low dose carbidopa-levodopa in untreated Parkinson patients. Pages 201-208 in S. Fahn, C. D. Marsden, D. Calne, and M. Goldstein, Eds., Recent Developments in Parkinson's Disease, Vol. 2. Macmillian, Florham Park, NJ.
50. 50. PAPA, S. M., AND T. N. CHASE. 1996. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39: 574-578.
51. 51. PARKINSON STUDY GROUP. 1989. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321: 1364-1371.
52. 52. PARKINSON STUDY GROUP. 1996a. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39: 29-36.
53. 53. PARKINSON STUDY GROUP. 1996b. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann. Neurol. 39: 37-45.
54. 54. PILLON, B., B. DUBOIS, AND Y. AGID. 1996. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 46: 329-334.
55. 55. PINDER, R. M., R. N. BROGDEN, P. R. SAWYER, et al. 1976. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in treatment of parkinsonism. Drugs 11: 329-377.
56. 56. QUINN, N. P., J. S. PERLMUTTER, AND C. D. MARSDEN. 1984. Acute administration of DL-threo DOPS does not affect the freezing phenomenon in parkinsonian patients. Neurology 34: 149A.
57. 57. RECHES, A. 1985. Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease. Clin. Neuropharmacol. 8: 249-259.
58. 58. RODNITSKY, R. L. 1992. The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Neurology 42(Suppl. 1): 44-50.
59. 59. SAMUEL, W., D. GALASKO, E. MASLIAH, AND L. A. HANSEN. 1996. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55: 44-52.
60. 60. SCHNEIDER, J. S. 1989. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 34: 193-196.
61. 61. ZETUSKY, W. J., J. JANKOVIC, AND F. J. PIROZZOLO. 1985. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology 35: 522-526.